In celebration of #NationalInternDay, we're spotlighting Chidiebube Chikezie, our Molecular Oncology Project Assistant from Portharcourt, Nigeria. Chidi, currently pursuing an MS at Georgetown University, shares, "Integrating classroom knowledge into real-world experience in molecular

📢 5 weeks to go! We’re excited to be giving a keynote presentation at Clinical Biomarkers & World CDx in September. Discover EpiSwitch® products for companion diagnostics in cancer #immunotherapy. Join us in Boston! Register: obdx.co/world-cdx-2024. #precisionmedicine #oncology #OBD #WorldCDx

.EpiSwitch CiRT is the focus of PROWES, a national IRB-approved study currently enrolling up to 2,500 patients across 12 #oncology institutions. This study will further evaluate CiRT's performance and demonstrate the test’s clinical utility in predicting immune checkpoint

🌍🔬 Today on #WorldLungCancerDay, we honor the strength and resilience of those affected by #lungcancer. At OBD, we reaffirm our commitment to advancing personalized healthcare with our #precisionmedicine tests, providing life-changing solutions to those in need. #WLCD24

OBD is proud to sponsor the ZERO Prostate Cancer Run/Walk in Houston, TX, this September! Join #TeamOBD in supporting the fight against #prostatecancer at mypse.co/TX2024. #ZEROoutprostatecancer

Just 2 weeks until Clinical Biomarkers & World CDx! Be sure to connect with our team and tune into OBD CSO’s Dr. Alexandre Akoulitchev’s keynote talk to discover EpiSwitch® products for companion diagnostics in cancer #immunotherapy: obdx.co/world-cdx-2024. #WorldCDx #PrecisionMedicine

Colleagues and collaborators are thrilled about the advancement of the PROWES study, which is further elucidating the clinical application and utility of CiRT for use in multiple oncological indications. The IRB-approved study is enrolling up to 2,500 patients across many

A leading oncologist from ESMO - Eur. Oncology emphasizes the need to ensure that new #prostatecancer screening methods don’t lead to unnecessary treatments. Men should have access to tests that provide accurate positive diagnoses. Read more in BBC News (UK) ⬇️ #pcsm bbc.com/news/articles/…

Be part of a team that's advancing personalized healthcare by developing #precisionmedicine tests for life-changing diseases. We're #hiring a Procurement Assistant and a Lab Technician in the UK. Make a real impact—apply today: obdx.co/careers. #JobOpening #LabTech

We’re inspired by ProstateCancerResearch’s push for a national #prostatecancer screening program. With 1 in 8 men affected, innovative solutions like our 94% accurate EpiSwitch® PSE test 94percent.com can minimize false positives and overtreatment, addressing current screening challenges.

Only 8 days to go! Join #TeamOBD on September 7th for the Houston @ZEROcancer Run/Walk. 1 in 8 men will be diagnosed with #prostatecancer, including 17,230 men in Texas this year alone. Let’s raise awareness and funds to help #ZEROoutprostatecancer: mypse.co/TX2024.

We’re kicking off a month dedicated to #prostatecancer awareness! Follow us 94percent.com for updates on how you can join us in education, advocacy, and support. Together, let’s empower men to take control of their #prostatehealth. #ProstateCancerAwarenessMonth #PCAM24

Read how The Telegraph journalist George Chesterton took our 94% accurate #prostatecancer detection test, which can minimize false positives and unnecessary treatments. Featuring insights from a UK clinical expert. #ProstateCancerAwareness #pcam24 #pcsm mypse.co/telegraph

Attending the #WorldCDx summit? Don’t miss tomorrow’s keynote talk by #OBD CSO, Dr. Alexandre Akoulitchev. Be sure to stop by our booth to discover the diagnostic, predictive, and prognostic power of the EpiSwitch® platform: myobdx.com. #PrecisionMedicine

Thanks Garrett D Pohlman, M.D. for sharing your clinical insights on using EpiSwitch® PSE with your patients. Check out this Grand Rounds Urology webinar to discover how our PSE test detects #prostatecancer with 94% accuracy, helping to reduce unnecessary biopsies 👇 #pcsm grandroundsinurology.com/episwitch-pros…

Dr. Alexandre Akoulitchev’s #WorldCDx keynote, "Companion Diagnostics for Immune Oncology with EpiSwitch & 3D Genomics," gave a deep dive into how the EpiSwitch® platform is helping tackle one of the biggest challenges in cancer immunotherapy—predicting patient responses. With

Survivors, advocates, healthcare providers, and families came together at the Houston ZERO Prostate Cancer Run/Walk to raise awareness and support men battling #ProstateCancer. 💙 Oxford BioDynamics is proud to have been a local sponsor of this incredible event and share our 94%

Simple sample, fast results. The EpiSwitch® PSE #prostatecancer blood test is designed for ease: blood draw, no sample manipulation, ambient shipping, and results within 5 days of the sample reaching our labs. Optimize your practice now! Learn more: 94percent.com. #pcsm

After multiple tests and unclear results, it felt like I was stuck in a loop—waiting, testing, and still no answers. The EpiSwitch® PSE #prostatecancer blood test changed that. It gave me and my doctor a clear path forward with 94% accuracy. Now, I can confidently take the next

The The Immunobuddies Podcast Podcast is talking EpiSwitch® CiRT! Tune in as Ricky Frazer and Anna Olsson-Brown discuss our immune checkpoint inhibitor response test with our very own Bartu Ahiska and Dr. Ryan Mathis: buzzsprout.com/2128662/episod…. #Cancer #Immunotherapy #PersonalizedMedicine #OBD